These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 14705765)

  • 1. Is fluoxetine an effective therapy for weight loss in obese patients?
    Epling J;
    Am Fam Physician; 2003 Dec; 68(12):2437-8. PubMed ID: 14705765
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of fluoxetine and placebo in the treatment of obesity.
    Fernández-Soto ML; González-Jiménez A; Barredo-Acedo F; Luna del Castillo JD; Escobar-Jiménez F
    Ann Nutr Metab; 1995; 39(3):159-63. PubMed ID: 7486842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity.
    Anchors M
    Arch Intern Med; 1997 Jun; 157(11):1270. PubMed ID: 9183245
    [No Abstract]   [Full Text] [Related]  

  • 4. Fluoxetine: a randomized clinical trial in the maintenance of weight loss.
    Goldstein DJ; Rampey AH; Dornseif BE; Levine LR; Potvin JH; Fludzinski LA
    Obes Res; 1993 Mar; 1(2):92-8. PubMed ID: 16350565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet.
    Huang CC; Chian CY; Lin JD
    Changgeng Yi Xue Za Zhi; 1998 Mar; 21(1):50-6. PubMed ID: 9607264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of long-term fluoxetine treatment of obesity--maximizing success.
    Goldstein DJ; Rampey AH; Roback PJ; Wilson MG; Hamilton SH; Sayler ME; Tollefson GD
    Obes Res; 1995 Nov; 3 Suppl 4():481S-490S. PubMed ID: 8697047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with Binge Eating Disorder.
    Leombruni P; Pierò A; Lavagnino L; Brustolin A; Campisi S; Fassino S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1599-605. PubMed ID: 18598735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoxetine-maintained obese humans: effect on food intake and body weight.
    Ward AS; Comer SD; Haney M; Fischman MW; Foltin RW
    Physiol Behav; 1999 Jul; 66(5):815-21. PubMed ID: 10405110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss.
    Maheux P; Ducros F; Bourque J; Garon J; Chiasson JL
    Int J Obes Relat Metab Disord; 1997 Feb; 21(2):97-102. PubMed ID: 9043962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity.
    Breum L; Bjerre U; Bak JF; Jacobsen S; Astrup A
    Metabolism; 1995 Dec; 44(12):1570-6. PubMed ID: 8786726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity.
    Arterburn D
    Clin Evid; 2004 Jun; (11):762-76. PubMed ID: 15652036
    [No Abstract]   [Full Text] [Related]  

  • 12. The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial.
    Pedrinola F; Sztejnsznajd C; Lima N; Halpern A; Medeiros-Neto G
    Obes Res; 1996 Nov; 4(6):549-54. PubMed ID: 8946439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonergic agents in the treatment of hypothalamic obesity syndrome: a case report.
    Jordaan GP; Roberts MC; Emsley RA
    Int J Eat Disord; 1996 Jul; 20(1):111-3. PubMed ID: 8807359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status.
    Whigham LD; Dhurandhar NV; Rahko PS; Atkinson RL
    Int J Obes (Lond); 2007 May; 31(5):850-7. PubMed ID: 17146452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy.
    Brunswick DJ; Amsterdam JD; Fawcett J; Quitkin FM; Reimherr FW; Rosenbaum JF; Beasley CM
    J Clin Psychopharmacol; 2001 Dec; 21(6):616-8. PubMed ID: 11763012
    [No Abstract]   [Full Text] [Related]  

  • 16. Fluoxetine for serotonin reuptake inhibitor discontinuation syndrome.
    Benazzi F
    J Psychiatry Neurosci; 1998 Sep; 23(4):241-2. PubMed ID: 9785704
    [No Abstract]   [Full Text] [Related]  

  • 17. [Neuroadaptive changes in brain during selective serotonin reuptake inhibitors action].
    Shishkina GT
    Ross Fiziol Zh Im I M Sechenova; 2007 Nov; 93(11):1245-51. PubMed ID: 18198592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Disorder of eating behavior and comorbid syndromes in obesity and methods of their correction].
    Voznesenskaia TG; Safonova VA; Platonova NM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(12):49-52. PubMed ID: 11195539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten years of fluoxetine.
    Stokes PE
    Depress Anxiety; 1998; 8 Suppl 1():1-4. PubMed ID: 9809207
    [No Abstract]   [Full Text] [Related]  

  • 20. Fluoxetine and eating disorders.
    Morgan JF
    Hosp Med; 1999 Sep; 60(9):686. PubMed ID: 10621803
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.